WHY SAPHNELO?
REDUCED DISEASE ACTIVITY
In clinical studies, SAPHNELO reduced disease activity across the different parts of the body and organs that lupus can affect, including improvements to the muscles, joints, and skin.*,†
SAPHNELO MAY ALSO PROVIDE ADDITIONAL BENEFITS FOR SOME PATIENTS
SIGNIFICANT STEROID REDUCTION
SAPHNELO is the only FDA-approved biologic for adults with moderate to severe lupus that’s proven to significantly lower steroid use.*,‡,§
FEWER FLARES
Some patients taking SAPHNELO had fewer flares compared to those who did not have SAPHNELO added to their other lupus medications.‖
EARLY RESPONSES REPORTED
Patients experienced improvements in their lupus symptoms; some within weeks after starting treatment.‖
RESULTS MAY VARY. TALK TO YOUR HEALTHCARE PROVIDER.
*Compared to other lupus medicines alone.
†Disease activity reduction at the end of treatment was statistically significant in 3 of the 4 studies.
‡A reduction in steroid use was seen in 4 studies, 1 of which was statistically significant.
§In some patients on oral steroids ≥10 mg/day at the study start, the oral steroid dose was reduced to ≤7.5 mg/day.
‖Based on the limitations of this study, results are descriptive and for information only. Your experience may differ.
TALK TO YOUR DOCTOR ABOUT SAPHNELO
This discussion guide is designed to help you start a conversation with your doctor about your lupus treatment goals and whether adding SAPHNELO could be right for you.
WHO IS SAPHNELO FOR?
SAPHNELO was studied in 3 clinical trials and is for adults with moderate to severe lupus who are on other lupus medications. In clinical trials, SAPHNELO was shown to work in patients of different races or ethnicities. Consistent results were seen across diverse groups of people, including Black, Hispanic/Latino, Asian, and White populations.
IN CLINICAL TRIALS, SAPHNELO PROVIDED CONSISTENT RESULTS ACROSS RACE OR ETHNICITY.
PEOPLE HAVE BEEN PRESCRIBED SAPHNELO FOR SLE IN THE US SINCE 2021.
SAPHNELO IS THE #1 PRESCRIBED BRAND FOR ADULT PATIENTS WITH LUPUS WHO ARE STARTING A NEW IV BIOLOGIC.
Learn how SAPHNELO offers flexibility with monthly IV infusions or weekly self-injections to fit your routine.
HEAR BRIE’S STORY
Adding SAPHNELO helped her feel more like herself again—with reduced lupus disease activity across her body and less oral steroid use.*,†
*Compared to other lupus medicines alone.
†In some patients on an oral steroid dose of ≥10 mg per day at study start, the oral steroid dose was reduced to ≤7.5 mg per day. Talk to your doctor before stopping or changing any medications.
Individual experiences may vary.
Lupus may affect everyone differently.
However, one common factor in lupus disease is IFN-1.
Tiny messengers in the body called type 1 interferons (IFN-1) send signals to activate the immune system. Too much IFN-1 can lead to immune problems.
IFN-1 plays a key role in lupus because it can send signals to several types of immune cells to attack your body.
none
SAPHNELO is the first and only treatment for adults with moderate to severe SLE who are receiving other lupus medicines that…
…blocks IFN-1 activity from sending signals to other immune cells to attack your body.
-
te
-
te
-
third
-
fourth
KEEP EXPLORING
STARTING SAPHNELO
Learn about the IV infusion and self-injection administration options for SAPHNELO.
IV INFUSIONSELF-INJECTIONTHANKS FOR REGISTERING!
THANKS FOR REGISTERING!
By completing this registration, I confirm that I am at least 18 years old, agree to receive information about SAPHNELO, and may receive information about other immunology medicines and services related to my condition which includes, but is not limited to, educational and promotional materials, special offers and services and for market research purposes, which includes contacting me to participate in focus groups, surveys or interviews. This may include AstraZeneca or a third party working on AstraZeneca's behalf contacting me by telephone, e-mail and text message regarding AstraZeneca Support Programs that may be of interest to me. Information provided by AstraZeneca does not take the place of talking to your healthcare provider about your treatment or condition. If you no longer want to receive health-related materials, call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.
By providing your phone number, you are opting in to receive updates and support messages from SAPHNELO. Text STOP to opt out. Text HELP for help. Message frequency will vary. Message and data rates may apply. For more information, visit Privacy Notice or Terms & Conditions.
IMPORTANT SAFETY INFORMATION
- Do not use SAPHNELO if you are allergic to anifrolumab-fnia or to any of the ingredients
- Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you:
- Think you have an infection or have an infection that keeps coming back
- Are scheduled to receive a vaccination or if you think you may need a vaccination. You should not receive live vaccines during treatment with SAPHNELO
- Have or have had cancer
- Are receiving other biologic medicines or monoclonal antibodies
- Are pregnant or plan to become pregnant. It is not known if SAPHNELO will harm your unborn baby. Tell your healthcare provider if you are, might be, or plan to become pregnant during treatment with SAPHNELO
- Pregnancy exposure registry monitors pregnancy outcomes in women exposed to SAPHNELO. You can find out more information about the registry by calling AstraZeneca at 1-877-693-9268
- Are breastfeeding or plan to breastfeed. It is not known if SAPHNELO passes into your breast milk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SAPHNELO may affect the way other medicines work, and other medicines may affect how SAPHNELO works.
SAPHNELO may cause serious side effects, including:
- Serious infections: SAPHNELO can lower the ability of your immune system to fight infections. You may be at a higher risk of developing respiratory infections and shingles (herpes zoster) during treatment with SAPHNELO. Infections could be serious, leading to hospitalization or death. Tell your healthcare provider right away if you have any of the following symptoms of an infection:
- fever, sweating, or chills
- muscle aches
- cough
- shortness of breath
- burning when urinating
- urinating more often
- diarrhea or stomach pain
- warm, red, or painful skin or sores on your body
- Allergic (hypersensitivity) reactions, including anaphylaxis: Serious allergic reactions can happen during or after SAPHNELO administration. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of a serious allergic reaction:
- swelling of your face, mouth, and tongue
- breathing problems
- fainting or dizziness
- feeling lightheaded (low blood pressure)
- Cancer: SAPHNELO may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers
The most common side effects of SAPHNELO include:
- Upper respiratory infections
- Bronchitis
- Infusion reactions (when given intravenously)
- Shingles (herpes zoster)
- Cough
These are not all the possible side effects of SAPHNELO. Call your healthcare provider for medical advice about side effects.
SAPHNELO is a prescription medicine used to treat adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.
It is not known if SAPHNELO is effective in patients with severe active lupus nephritis or severe active central nervous system lupus. It is not known if SAPHNELO is safe and effective in patients under 18 years of age.
Please see full Prescribing Information, including Patient Information.
You may report side effects related to AstraZeneca productsOpens new window.
IMPORTANT SAFETY INFORMATION
^
IMPORTANT SAFETY INFORMATION
Treatment Start Date
We ask this so that we may send you check-ins and updates in a timely manner.